News from the World of Clinical Research

Spring Ethics & GCP Forum Friday 19th April

Tickets are NOW ON SALE for our Spring Ethics & GCP Forum at University College London on Friday 19th April. Lord O'Shaughnessy will be presenting in person! So book early to avoid disappointment!…

In wake of Reata buyout, Biogen's key launch Skyclarys passes muster in EU

Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting …

NIHR awards over £20m to eight new global health research projects

The National Institute for Health and Care Research (NIHR) has awarded over £20m to eight new global health research projects to strengthen health service delivery and resilience in low- and middle-in…

AstraZeneca 'body checks' cancer in NHL-partnered screening push

AstraZeneca is working with the NHL to encourage people to “Get Body Checked Against Cancer.” The campaign is designed to encourage sports fans to ask their doctors about available cancer screenings a…

Rapid rollout of NHS blood-thinning drugs has saved thousands of lives

Since 2022, an estimated 17,000 strokes and 4,000 deaths have been prevented

The NHS has revealed that thousands of lives have been saved and around 17,000 strokes prevented due to the rapid roll-out …

Lilly, Boehringer run 'It takes 2' campaign with hip-hop artist Rob Base for kidney disease awarenessThe obesity drug effect: What medical device executives are saying

Jardiance development partners Eli Lilly and Boehringer Ingelheim say it takes two: two tests, to be exact, to find out about a patient’s kidney disease.

That sparked a memory, one going all the way b…

Dr Know

The world we’re living in is changing rapidly and the future of health is being profoundly shaped by several interconnected factors.

Five Trends Set to Disrupt Health Marketing in 2024

The media marketplace’s shifting dynamics have reached tectonic proportion with reshuffles at emergent platforms and effects of union strikes shaking up media’s Grand Dame – Hollywood. Despite the myr…

Vertex gearing up for launch as sickle cell therapy review advances

By early December, the Food and Drug Administration will decide on approval of a genetic medicine for sickle cell disease, potentially offering people with the rare blood condition a new, sought-after…

Moods change with the months? Bausch has a seasonal depression drug TV campaign for you

With the nights drawing in, Bausch Health is taking the plunge on the first-ever TV spot for its seasonal affective disorder (SAD) drug Aplenzin. The ad is designed to encourage people who withdraw, o…

UK launches its first national PET imaging platform for drug discovery

NPIP will transform medical research and provide better outcomes for patients

The Medicines Discovery Catapult (MDC), the Medical Research Council (MRC) and Innovative UK has announced the launch of t…

Astellas starts Veozah TV push, pitching menopause drug as how to go from hot flashes to not flashes

Astellas’ mission to turn menopause drug Veozah into a major product is ratcheting up a gear, with the drugmaker hitting go on a TV spot centered on how the recently approved therapy turns hot flashes…

Trials of the century

Overcoming operational hurdles and igniting clinical trials

In an era characterised by remarkable breakthroughs in drug discovery, development and biotech innovation, many say we’re in the midst of a …

Site Enablement: How Sponsors and CROs Can Enhance Their Clinical Trials in a Competitive Landscape

The evolution of clinical research has been dependent on the conversion of Healthcare Organizations (HCOs) to clinical research sites, along with the conversion of Healthcare Providers (HCPs) to Princ…

Opening doors

Following in their footsteps – the young people choosing to follow their parents into the pharmaceutical industry

Pharma has changed a lot in recent years. The rules and regulations surrounding develo…

J&J to phase out Janssen name in corporate rebrand

Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as part of a corporate rebranding in th…

NICE gives green light for MSD's Keytruda

The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study

MSD has revealed that the National Institute for Health and Care Excellence (NICE) has recommended the use of …

Biogen kicks off 1,000 layoffs as part of CEO Chris Viehbacher's 'complete redesign'

It was only last spring that Biogen started a round of layoffs that eventually shrank the company’s head count by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions …

Men with enlarged prostates offered robotic treatment by fourth University Hospital

Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue

The Norfolk and Norwich University Hospitals (NNUH) Urology team have become the first in the East of England…

Autumn Ethics & GCP Forum - ONLINE - Friday 17th November 2023

To book via Eventbrite and see the full agenda visit our Website

If you have any questions please email office@icr-global.org 

Green light for one of Europe’s largest life sciences campus

Reef Group and UBS Asset Management have gained approval to develop one of Europe’s largest life sciences campuses in Stevenage, UK.

Family of Henrietta Lacks sues Ultragenyx over use of HeLa cell line

The family of Henrietta Lacks is suing rare disease drug developer Ultragenyx over its use of technology built from her cells, which were taken without her knowledge or consent in 1951 and immortalize…

Cannabinoid company expands into oncology

Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it…

Build a More Participant-Focused Trial: Amplify the Patient Voice in Clinical Research Technology Development

For those of us who use sophisticated digital tools every day, it’s easy to assume that technology always makes life easier. It doesn’t.

TauRx’s deliver Alzheimer’s disease therapy results

TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial.

The study measured the effect of hydromethylthionine mes…